JOP20220035A1 - مواد وطرق لتحسين أجزاء المتغير أحادي السلسلة - Google Patents
مواد وطرق لتحسين أجزاء المتغير أحادي السلسلةInfo
- Publication number
- JOP20220035A1 JOP20220035A1 JOP/2022/0035A JOP20220035A JOP20220035A1 JO P20220035 A1 JOP20220035 A1 JO P20220035A1 JO P20220035 A JOP20220035 A JO P20220035A JO P20220035 A1 JOP20220035 A1 JO P20220035A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- materials
- chain variator
- optimizing single
- parts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Oxygen, Ozone, And Oxides In General (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Sampling And Sample Adjustment (AREA)
- Ropes Or Cables (AREA)
- Glass Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962887519P | 2019-08-15 | 2019-08-15 | |
| US201962887529P | 2019-08-15 | 2019-08-15 | |
| US201962887514P | 2019-08-15 | 2019-08-15 | |
| US201962887524P | 2019-08-15 | 2019-08-15 | |
| US201962887527P | 2019-08-15 | 2019-08-15 | |
| US201962946886P | 2019-12-11 | 2019-12-11 | |
| US201962946897P | 2019-12-11 | 2019-12-11 | |
| US201962946865P | 2019-12-11 | 2019-12-11 | |
| US201962946877P | 2019-12-11 | 2019-12-11 | |
| US201962946882P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/046303 WO2021030657A1 (en) | 2019-08-15 | 2020-08-14 | Materials and methods for improved single chain variable fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220035A1 true JOP20220035A1 (ar) | 2023-01-30 |
Family
ID=72243247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2022/0035A JOP20220035A1 (ar) | 2019-08-15 | 2022-02-10 | مواد وطرق لتحسين أجزاء المتغير أحادي السلسلة |
Country Status (19)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021116337A1 (en) * | 2019-12-11 | 2021-06-17 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| AR125210A1 (es) * | 2021-03-24 | 2023-06-21 | Janssen Biotech Inc | Anticuerpos dirigidos a cd22 y cd79b |
| EP4436669A1 (en) * | 2021-11-22 | 2024-10-02 | Janssen Biotech, Inc. | Compositions comprising enhanced multispecific binding agents for an immune response |
| WO2023152581A1 (en) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Method of treating cancer with psmaxcd3 antibody |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| EP4565331A1 (en) | 2022-08-05 | 2025-06-11 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
| CN120077064A (zh) | 2022-08-05 | 2025-05-30 | 詹森生物科技公司 | 用于治疗脑肿瘤的转铁蛋白受体结合蛋白 |
| CN121925428A (zh) | 2023-07-30 | 2026-04-24 | 詹森生物科技公司 | 结合突变钙网蛋白的分子及其用途 |
| EP4758173A1 (en) | 2023-08-07 | 2026-06-17 | Janssen Biotech, Inc. | Enpp3 and cd3 binding agents and methods of use thereof |
| AU2024321510A1 (en) | 2023-08-07 | 2026-03-26 | Janssen Biotech, Inc. | Stabilized cd3 antigen binding agents and methods of use thereof |
| IL326398A (en) * | 2023-08-07 | 2026-04-01 | Janssen Biotech Inc | Gucy2c antibodies and uses thereof |
| KR20260081298A (ko) | 2023-08-28 | 2026-06-02 | 젠코어 인코포레이티드 | 항-cd20 x 항-cd28 조합 요법 |
| WO2025088587A1 (en) * | 2023-10-27 | 2025-05-01 | Janssen Biotech, Inc. | Compositions comprising enhanced multispecific binding agents for an immune response |
| US20250376509A1 (en) | 2023-11-21 | 2025-12-11 | Janssen Biotech, Inc. | Methods for treatment of myeloproliferative neoplasms |
| AU2024401943A1 (en) | 2023-12-12 | 2026-07-30 | Janssen Biotech, Inc. | Enpp3 × cd3 bispecific antibodies and use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025172924A1 (en) | 2024-02-15 | 2025-08-21 | Janssen Biotech, Inc. | Anti-transferrin receptor compositions and methods thereof |
| US20250361317A1 (en) | 2024-05-24 | 2025-11-27 | Janssen Biotech, Inc. | Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19 |
| WO2025251110A1 (en) * | 2024-06-03 | 2025-12-11 | Selvax Pty Ltd | Anti-cd40 antibody il-2 fusion proteins |
| WO2025259749A1 (en) * | 2024-06-12 | 2025-12-18 | Amgen Inc. | Stable single-chain variable fragments |
| WO2026035888A1 (en) | 2024-08-06 | 2026-02-12 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| WO2026055669A2 (en) | 2024-09-09 | 2026-03-12 | Xencor, Inc. | Anti-tl1a x anti-il23 antibodies |
| WO2026093993A1 (en) | 2024-11-01 | 2026-05-07 | Janssen Biotech, Inc. | Methods and systems for enhanced multispecific metabolic and cellular targeting |
| WO2026136805A1 (en) | 2024-12-19 | 2026-06-25 | Agni Bio, Inc. | Methods and compositions for modulating v-beta-17 chain mediated immunity |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EA015992B1 (ru) * | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CA2682851C (en) | 2007-04-02 | 2017-01-17 | Philogen S.P.A. | A novel antigen associated with the neovasculature of tumour metastases |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| RU2582244C2 (ru) * | 2008-06-30 | 2016-04-20 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | Функционализированные полипептиды |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| RU2583876C2 (ru) | 2009-08-17 | 2016-05-10 | Роше Гликарт Аг | Иммуноконъюгаты направленного действия |
| WO2011030107A1 (en) * | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| CA2784610C (en) * | 2009-12-23 | 2020-07-14 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
| GB201005064D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| TWI622597B (zh) * | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| IN2014CN03887A (cg-RX-API-DMAC7.html) | 2011-10-27 | 2015-10-16 | Genmab As | |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| JP5550797B2 (ja) | 2012-05-24 | 2014-07-16 | パナソニック株式会社 | ヒト心筋由来トロポニンiに特異的にかつ速やかに結合できる変異体タンパク質 |
| PT2970980T (pt) | 2013-03-15 | 2018-11-19 | Janssen Biotech Inc | Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes |
| US20160326249A1 (en) * | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| CN109843926B (zh) | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | 针对cd3的双特异性抗体 |
| EP3684816B1 (en) | 2017-09-22 | 2024-05-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
| GB201721421D0 (en) * | 2017-12-20 | 2018-01-31 | Ucl Business Plc | Chimeric antigen receptor |
-
2020
- 2020-08-14 TW TW109127754A patent/TW202120537A/zh unknown
- 2020-08-14 BR BR112022002540A patent/BR112022002540A2/pt unknown
- 2020-08-14 JP JP2022507875A patent/JP7797373B2/ja active Active
- 2020-08-14 CA CA3148121A patent/CA3148121A1/en active Pending
- 2020-08-14 MX MX2022001799A patent/MX2022001799A/es unknown
- 2020-08-14 WO PCT/US2020/046303 patent/WO2021030657A1/en not_active Ceased
- 2020-08-14 US US16/994,065 patent/US11787875B2/en active Active
- 2020-08-14 CN CN202080057404.8A patent/CN114258400A/zh active Pending
- 2020-08-14 EP EP20761987.5A patent/EP4013783A1/en active Pending
- 2020-08-14 PH PH1/2022/550348A patent/PH12022550348A1/en unknown
- 2020-08-14 PE PE2022000220A patent/PE20220299A1/es unknown
- 2020-08-14 KR KR1020227004708A patent/KR20220062494A/ko active Pending
- 2020-08-14 CR CR20220054A patent/CR20220054A/es unknown
- 2020-08-14 AU AU2020328049A patent/AU2020328049A1/en active Pending
-
2022
- 2022-02-07 CO CONC2022/0001222A patent/CO2022001222A2/es unknown
- 2022-02-08 DO DO2022000032A patent/DOP2022000032A/es unknown
- 2022-02-08 IL IL290436A patent/IL290436A/en unknown
- 2022-02-10 JO JOP/2022/0035A patent/JOP20220035A1/ar unknown
- 2022-02-11 EC ECSENADI202211199A patent/ECSP22011199A/es unknown
-
2023
- 2023-09-05 US US18/461,191 patent/US20240067754A1/en active Pending
-
2025
- 2025-03-17 JP JP2025042288A patent/JP2025094049A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210047435A1 (en) | 2021-02-18 |
| EP4013783A1 (en) | 2022-06-22 |
| JP2022544760A (ja) | 2022-10-21 |
| DOP2022000032A (es) | 2022-07-31 |
| AU2020328049A1 (en) | 2022-02-17 |
| BR112022002540A2 (pt) | 2022-06-14 |
| ECSP22011199A (es) | 2022-03-31 |
| US20240067754A1 (en) | 2024-02-29 |
| US11787875B2 (en) | 2023-10-17 |
| PH12022550348A1 (en) | 2022-12-12 |
| IL290436A (en) | 2022-04-01 |
| CA3148121A1 (en) | 2021-02-18 |
| JP2025094049A (ja) | 2025-06-24 |
| JP7797373B2 (ja) | 2026-01-13 |
| KR20220062494A (ko) | 2022-05-17 |
| MX2022001799A (es) | 2022-03-11 |
| CO2022001222A2 (es) | 2022-03-08 |
| PE20220299A1 (es) | 2022-03-07 |
| CN114258400A (zh) | 2022-03-29 |
| CR20220054A (es) | 2022-06-06 |
| TW202120537A (zh) | 2021-06-01 |
| WO2021030657A1 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001799A (es) | Materiales y metodos para fragmentos variables de cadena unica mejorados. | |
| CL2020000596S1 (es) | Auriculares. | |
| CL2020000894S1 (es) | Control manual inalámbrico. | |
| CL2020000594S1 (es) | Estuche de auriculares. | |
| CY1122653T1 (el) | Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων | |
| CL2019001554S1 (es) | Automóvil. | |
| CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| PH12022550646A1 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| MX2017011432A (es) | Anticuerpos contra cumulo de diferenciacion 48 (cd48) y sus conjugados. | |
| MX385456B (es) | Anticuerpos cd123 y conjugados de los mismos. | |
| CL2019002232S1 (es) | Automóvil. | |
| CL2020001201S1 (es) | Automóvil. | |
| CL2018003838S1 (es) | Botella. | |
| EA201991818A1 (ru) | Лечение рака | |
| JOP20190190B1 (ar) | معالجة سرطان | |
| EA201892368A1 (ru) | ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ | |
| CL2020000224S1 (es) | Automóvil. | |
| MY206087A (en) | Combination of factor vii and an anti-factor ix/x bispecific antibody | |
| WO2019133902A3 (en) | Antibodies and assays for ccl14 | |
| CL2019001469S1 (es) | Cepillo de dientes. | |
| CL2019001123S1 (es) | Cepillo de dientes. | |
| CL2020000320S1 (es) | Contenedor de alimentos. | |
| EA202193121A1 (ru) | Лечение рака | |
| CL2019001470S1 (es) | Cepillo de dientes. | |
| CL2019001121S1 (es) | Cepillo de dientes. |